Notice: This company has been marked as potentially delisted and may not be actively trading. Alterity Therapeutics (PRAN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends PRAN vs. NKTX, ADCT, ENTA, ACTU, NVCT, SLN, MCRB, PBYI, BMEA, and TSVTShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Nkarta (NKTX), ADC Therapeutics (ADCT), Enanta Pharmaceuticals (ENTA), Actuate Therapeutics (ACTU), Nuvectis Pharma (NVCT), Silence Therapeutics (SLN), Seres Therapeutics (MCRB), Puma Biotechnology (PBYI), Biomea Fusion (BMEA), and 2seventy bio (TSVT). These companies are all part of the "medical" sector. Alterity Therapeutics vs. Nkarta ADC Therapeutics Enanta Pharmaceuticals Actuate Therapeutics Nuvectis Pharma Silence Therapeutics Seres Therapeutics Puma Biotechnology Biomea Fusion 2seventy bio Nkarta (NASDAQ:NKTX) and Alterity Therapeutics (NASDAQ:PRAN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability. Which has better valuation and earnings, NKTX or PRAN? Alterity Therapeutics has higher revenue and earnings than Nkarta. Alterity Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNkartaN/AN/A-$117.50M-$1.88-1.09Alterity Therapeutics$150K242.08-$6.40M-$0.70-5.83 Is NKTX or PRAN more profitable? Alterity Therapeutics' return on equity of 0.00% beat Nkarta's return on equity.Company Net Margins Return on Equity Return on Assets NkartaN/A -27.13% -21.67% Alterity Therapeutics N/A N/A N/A Do insiders & institutionals have more ownership in NKTX or PRAN? 80.5% of Nkarta shares are owned by institutional investors. Comparatively, 3.6% of Alterity Therapeutics shares are owned by institutional investors. 8.7% of Nkarta shares are owned by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community prefer NKTX or PRAN? Alterity Therapeutics received 128 more outperform votes than Nkarta when rated by MarketBeat users. However, 76.92% of users gave Nkarta an outperform vote while only 57.67% of users gave Alterity Therapeutics an outperform vote. CompanyUnderperformOutperformNkartaOutperform Votes6076.92% Underperform Votes1823.08% Alterity TherapeuticsOutperform Votes18857.67% Underperform Votes13842.33% Does the media prefer NKTX or PRAN? In the previous week, Nkarta had 4 more articles in the media than Alterity Therapeutics. MarketBeat recorded 6 mentions for Nkarta and 2 mentions for Alterity Therapeutics. Nkarta's average media sentiment score of 1.21 beat Alterity Therapeutics' score of 0.00 indicating that Nkarta is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nkarta 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alterity Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, NKTX or PRAN? Nkarta has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Do analysts recommend NKTX or PRAN? Nkarta presently has a consensus price target of $15.00, indicating a potential upside of 631.71%. Given Nkarta's stronger consensus rating and higher possible upside, research analysts plainly believe Nkarta is more favorable than Alterity Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nkarta 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Alterity Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryNkarta beats Alterity Therapeutics on 9 of the 17 factors compared between the two stocks. Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAN vs. The Competition Export to ExcelMetricAlterity TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.31M$7.05B$5.84B$9.14BDividend YieldN/A2.75%4.75%3.86%P/E Ratio-5.836.1126.7719.18Price / Sales242.08268.25435.4570.78Price / CashN/A65.6738.0134.83Price / Book2.916.707.644.62Net Income-$6.40M$138.98M$3.19B$246.06M Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRANAlterity TherapeuticsN/A$4.08-2.6%N/A+105.4%$36.31M$150,000.00-5.8314NKTXNkarta2.6476 of 5 stars$2.21+4.2%$15.00+578.7%-78.5%$155.96MN/A-1.18140Positive NewsADCTADC Therapeutics2.8827 of 5 stars$1.61-0.3%$8.00+398.4%-65.1%$155.19M$69.56M-0.67310Short Interest ↓ENTAEnanta Pharmaceuticals4.0608 of 5 stars$7.14-4.8%$17.25+141.6%-38.1%$152.30M$67.64M-1.30160Analyst UpgradeACTUActuate TherapeuticsN/A$7.76+0.4%N/AN/A$151.55MN/A0.0010NVCTNuvectis Pharma2.4021 of 5 stars$7.80+12.2%$21.00+169.2%+7.2%$150.70MN/A-6.728High Trading VolumeSLNSilence Therapeutics2.164 of 5 stars$4.84+7.6%$45.00+829.8%-79.9%$144.86M$31.55M-3.08100MCRBSeres Therapeutics3.9667 of 5 stars$0.83-0.9%$5.08+510.5%-23.5%$142.18M$126.32M-3.62330News CoveragePBYIPuma Biotechnology3.7423 of 5 stars$2.86-1.7%$7.00+144.8%-55.5%$140.40M$235.60M5.96200Upcoming EarningsNews CoverageBMEABiomea Fusion3.3236 of 5 stars$3.73+3.3%$39.36+955.3%-77.4%$135.17MN/A-0.9350Positive NewsTSVT2seventy bio2.1794 of 5 stars$2.54-0.4%$7.20+183.5%-53.2%$131.03M$45.62M-1.37440Analyst ForecastNews CoveragePositive News Related Companies and Tools Related Companies Nkarta Competitors ADC Therapeutics Competitors Enanta Pharmaceuticals Competitors Actuate Therapeutics Competitors Nuvectis Pharma Competitors Silence Therapeutics Competitors Seres Therapeutics Competitors Puma Biotechnology Competitors Biomea Fusion Competitors 2seventy bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PRAN) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredCritical ‘Buy Now’ Alert on My Favorite Stock!My absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
